RPS-Strategy Redefined - Clinical Trials Asia

Pacra Portal

GCP Navigator
GCP Navigator
GCP Guidelines on your fingertips
Download it now. Click here

RSS Feed

  • Merck just accomplished a feat its rivals haven’t so far. England’s influential cost-effectiveness gatekeepers backed Keytruda, the company's immuno-oncology drug, to treat bladder cancer patients, becoming the first I-O med to win their favor in that cancer type.

  • Hikma has already cut 200 jobs since picking up generics business Roxane Labs from Boehringer Ingelheim. But more layoffs are coming.

  • Please don’t go, Ian Read. That’s the message Pfizer’s board of directors has made loud and clear to the almost-65-year-old CEO, as the company navigates a host of challenges.

  • Bayer is struggling with more than just sales at its important consumer health business. This week, the company kicked off another Alka-Seltzer recall because some packages were labeled with ingredients mismatched with the drugs inside. It's Bayer's second recall on that product in less than a year.

  • The Chinese government creates new drug regulator amid a widespread structural overhaul; Celltrion's manufacturing issues might delay Teva's migraine drug until 2019; Wuxi NextCODE and Google Cloud partner to set up a platform standard for genome data; plus more pharma industry news from Asia.

  • Indian drugmaker Dr. Reddy’s said that following an inspection, the FDA issued a Form 483 to its API Hyderabad Plant 1, citing four issues.

  • Investors who pressed GlaxoSmithKline to slash CEO Emma Walmsley’s pay package before she took the helm last March probably won’t much like her overall compensation figure for 2017.

  • This spring, U.K. consumers will be able to nab a package of Viagra without a prescription. And Pfizer's getting ready for that over-the-counter launch with its "largest ever" pharmacist training program there.

  • Just over four months ago, Allergan CEO Brent Saunders told investors in no uncertain terms that a breakup of the company was “not on the table.” But now? All bets are off.

  • The biopharma industry faced plenty of uncertainty in 2017, but for most companies, the year delivered a rebound from stagnation, EP Vantage reports. Some rebounded far more than others—and some went the other direction.

  • © 2018 PACRA. All Rights Reserved.
    Powered by: Visual Sparks Technologies